These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32617515)

  • 1. Pulsed Levosimendan in advanced heart failure due to congenital heart disease: a case series.
    Cranley J; Hardiman A; Freeman LJ
    Eur Heart J Case Rep; 2020 Jun; 4(3):1-6. PubMed ID: 32617515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.
    Altenberger J; Parissis JT; Costard-Jaeckle A; Winter A; Ebner C; Karavidas A; Sihorsch K; Avgeropoulou E; Weber T; Dimopoulos L; Ulmer H; Poelzl G
    Eur J Heart Fail; 2014 Aug; 16(8):898-906. PubMed ID: 24920349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis.
    Zhou S; Zhang L; Li J
    Herz; 2019 Nov; 44(7):630-636. PubMed ID: 29637229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.
    García-González MJ; Aldea Perona A; Lara Padron A; Morales Rull JL; Martínez-Sellés M; de Mora Martin M; López Díaz J; López Fernandez S; Ortiz Oficialdegui P; Jiménez Sosa A
    ESC Heart Fail; 2021 Dec; 8(6):4820-4831. PubMed ID: 34716753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
    Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
    ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
    Pölzl G; Altenberger J; Baholli L; Beltrán P; Borbély A; Comin-Colet J; Delgado JF; Fedele F; Fontana A; Fruhwald F; Giamouzis G; Giannakoulas G; Garcia-González MJ; Gustafsson F; Kaikkonen K; Kivikko M; Kubica J; von Lewinski D; Löfman I; Malfatto G; Manito N; Martínez-Sellés M; Masip J; Merkely B; Morandi F; Mølgaard H; Oliva F; Pantev E; Papp Z; Perna GP; Pfister R; Piazza V; Bover R; Rangel-Sousa D; Recio-Mayoral A; Reinecke A; Rieth A; Sarapohja T; Schmidt G; Seidel M; Störk S; Vrtovec B; Wikström G; Yerly P; Pollesello P
    Int J Cardiol; 2017 Sep; 243():389-395. PubMed ID: 28571618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotropes in Patients with Advanced Heart Failure: Not Only Palliative Care.
    Masarone D; Melillo E; Gravino R; Errigo V; Martucci ML; Caiazzo A; Petraio A; Pölzl G; Pacileo G
    Heart Fail Clin; 2021 Oct; 17(4):587-598. PubMed ID: 34511207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
    Pölzl G; Allipour Birgani S; Comín-Colet J; Delgado JF; Fedele F; García-Gonzáles MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Vrtovec B; Wikström G; Altenberger J
    ESC Heart Fail; 2019 Feb; 6(1):174-181. PubMed ID: 30378288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan in pulmonary hypertension and right heart failure.
    Hansen MS; Andersen A; Nielsen-Kudsk JE
    Pulm Circ; 2018; 8(3):2045894018790905. PubMed ID: 29979110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial.
    Pölzl G; Altenberger J; Comín-Colet J; Delgado JF; Fedele F; García-González MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Maier S; Vrtovec B; Wikström G; Zima E; Bauer A;
    Eur J Heart Fail; 2023 Nov; 25(11):2007-2017. PubMed ID: 37634941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
    Milwidsky A; Frydman S; Laufer-Perl M; Sadeh B; Sapir O; Granot Y; Hochstadt A; Korotetski L; Ketchker L; Topilsky Y; Banai S; Havakuk O
    ESC Heart Fail; 2022 Apr; 9(2):1487-1491. PubMed ID: 35083882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
    Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
    J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.
    Silvetti S; Belletti A; Fontana A; Pollesello P
    ESC Heart Fail; 2017 Nov; 4(4):595-604. PubMed ID: 28834396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent levosimendan infusions in advanced heart failure: a real world experience.
    Ortis B; Villani A; Oldani M; Giglio A; Ciambellotti F; Facchini M; Parati G; Malfatto G
    J Int Med Res; 2017 Feb; 45(1):361-371. PubMed ID: 28222634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated Levosimendan Infusions in the Management of Advanced Heart Failure: Review of the Evidence and Meta-analysis of the Effect on Mortality.
    Silvetti S; Pollesello P; Belletti A
    J Cardiovasc Pharmacol; 2024 Feb; 83(2):144-157. PubMed ID: 37991393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.